SAB Biotherapeutics (SABS) Other financing activities (2020 - 2026)
SAB Biotherapeutics (SABS) reported Other financing activities of $4571.0 for Q1 2026, up 120.61% on a YoY basis from $2072.0 in Q1 2025, and down 6.35% quarter-over-quarter from $4881.0 in Q3 2025.
SAB Biotherapeutics (SABS) Other financing activities (2020 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Other financing activities for 7 years, with the latest figure at $4571.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities rose 120.61% year-over-year to $4571.0; the trailing twelve-month figure through Mar 2026 stood at $31936.0 (up 19.15% YoY), and the FY2025 full-year result was $11205.0, down 45.1% from the prior year.
- Other financing activities for Q1 2026 stood at $4571.0, down from $4881.0 in the prior quarter.
- The five-year high for Other financing activities was $69141.0 in Q2 2022, with the low at $1890.0 in Q1 2023.
- Historically, Other financing activities has averaged $14153.4 across 5 years, with a median of $4726.0 in 2025.
- Annual changes were most pronounced in 2022 — Other financing activities slumped 97.76% — and 2024, when it jumped 980.0%.
- SAB Biotherapeutics' Other financing activities stood at $69141.0 in 2022, then plunged by 96.49% to $2430.0 in 2023, then soared by 740.0% to $20412.0 in 2024, then slumped by 76.09% to $4881.0 in 2025, then retreated by 6.35% to $4571.0 in 2026.
- The last three Other financing activities figures came in at $4571.0 (Q1 2026), $4881.0 (Q3 2025), and $2072.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,571.00 |
| Mar 31, 2026 | 4,571.00 |
| Sep 30, 2025 | 4,881.00 |
| Sep 30, 2025 | 4,881.00 |
| Mar 31, 2025 | 2,072.00 |
| Mar 31, 2025 | 2,072.00 |
| Mar 31, 2024 | 20,412.00 |
| Mar 31, 2024 | 20,412.00 |
| Sep 30, 2023 | 2,430.00 |
| Sep 30, 2023 | 2,430.00 |
| Mar 31, 2023 | 1,890.00 |
| Mar 31, 2023 | 1,890.00 |
| Jun 30, 2022 | 69,141.00 |
| Jun 30, 2022 | 69,141.00 |
| Mar 31, 2022 | 7,830.00 |
| Mar 31, 2022 | 7,830.00 |
| Dec 31, 2021 | -201,477.00 |
| Dec 31, 2021 | -201,477.00 |
| Jun 30, 2021 | -140,888.00 |
| Jun 30, 2021 | -140,888.00 |